Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by bigmack1on Aug 12, 2016 8:12pm
173 Views
Post# 25137938

Is there something that I am missing?

Is there something that I am missing? I rarely post but am very curious about the reason or reasons that could be keeping V.ATE at its current SP. Phase II is great news and the stock seems to be loosing much of the ground that was gained on the good news (profit taking). I appreciate that the company has been focusing on the Science and not so much on a massive pump. However, surely more savy investors or big money would see a buying opportunity if it existed. It looks to me like a text book time to buy. 1. good news 2. pull back after the good news 3. SP significantly discounted compared to just before it tanked do to HC asking for some revisions. 

I would really appreciate it if someone could help identify some forseable risks. I understand that financing will be an issue in terms of a succesful Phase III, perhaps a fear of iminent dilution? TIA and TGIF!

Bullboard Posts